Pharma Companies

Sun Pharma launches Leqselvi in US after patent settlement with Incyte Corp

Sun Pharma will pay Incyte an upfront fee and royalties to market Leqselvi in the US for alopecia areata until patent expiry in FY26 following a litigation settlement

GMP, NSQ compliance: MSME pharmaceutical companies seek financial aid

Pharma MSMEs seek Rs 50 crore handholding and extension for GMP compliance under revised Schedule M, citing challenges in adhering to regulatory and quality standards

HC-ordered expert panel for weight loss drug may be set up by mid-July

A Delhi HC directive to examine unregulated use of weight loss drugs may lead to a CDSCO expert panel by mid-July, possibly led by DCGI with pharma and govt representation

Biocon eyes early lead in generic Wegovy, Ozempic sales in Canada from 2026

The Bengaluru-based company is seeking approval of generic Ozempic by September from Canadian authorities, and also in some emerging markets, its managing director, Siddharth Mittal said

Lupin carves out consumer healthcare biz into wholly owned subsidiary

The carve-out will be effective from 1 July 2025, according to the company's regulatory filing on the exchanges.

Govt, Sigachi to pay ₹1 cr compensation to blast victims: Telangana CM

Telangana Chief Minister Revanth Reddy on Tuesday said his government will engage with the management of Sigachi Industries Ltd to ensure that a compensation of Rs 1 crore is paid to the kin of those who died in the explosion at the pharma plant in Pashamylaram. Reddy, who visited the blast site, said the toll from the explosion rose to 36. The CM also said those who are seriously injured will receive Rs 10 lakh, while those who are injured but can resume work after some recovery will be provided Rs 5 lakh. The state government will talk to the company management that Rs 1 crore each compensation will be paid to the deceased families. I have issued orders that from both the government side and company side Rs 1 Crore compensation will be paid, the CM said. Also, the state government will pay Rs 1 lakh each to the families of the deceased and Rs 50,000 to the injured to meet any immediate and emergency expenses. According to information provided by the officials, most of the deceas

Telangana factory blast toll rises to 36; CM announces ₹1 cr for each kin

The toll in the explosion at the Sigachi Industries' pharma plant in Pashamylaram has rose to 34, a senior police official said on Tuesday. "Several bodies have been found under the debris while removing it. As many as 31 bodies have been extricated from the debris while three died in hospital while undergoing treatment. The last leg of the rescue operation is still going on," district Superintendent of Police Paritosh Pankaj told PTI. Chief Minister A Revanth Reddy would visit the accident site Tuesday morning, Health Minister C Damodar Rajanarasimha said. The fatal accident on Monday is suspected to have been caused by a chemical reaction. Sigachi Industries Limited is a pharmaceutical company dedicated to pioneering advancements in Active Pharmaceutical Ingredients (APIs), Intermediates, Excipients, vitamin-mineral blends, and Operations and Management (O&M) services, according to the company's website.

Biocon's ₹4,500 crore equity raise to reduce debt by FY26, says S&P

S&P says Biocon will bring down adjusted debt to Rs 20,000 crore by FY26 through equity issuance, with strong cash flows aiding deleveraging and future capex needs

Eli Lilly's weekly insulin efsitora shows positive results in Phase 3

The company plans to submit efsitora, its once-weekly insulin for type 2 diabetes, to global regulators by end-2026 following positive Phase 3 trial outcomes

P&G Health Q4 net profit rises 31% to ₹61 crore on strong branding

Procter & Gamble Health Ltd on Thursday said its net profit jumped 31 per cent to Rs 61 crore in the January-March quarter. Net sales for the quarter rose 23 per cent to Rs 304 crore over the same period of the last year, P&G Health said in a statement. Financial performance was boosted by superior brand-building activities and supported by strengthened supply chain and go-to-market capabilities, it said. P&G Health also announced that it has changed its financial year from July 1-June 30 to April 1- March 31. The current financial year of the company covers a period of 9 months, from July 1, 2024, to March 31, 2025. For the nine-month fiscal year ended March 31, 2025, the company recorded sales of Rs 918 crore, up 8 per cent compared to the same nine-month period a year ago. For the period under review, the reported profit after tax stood at Rs 234 crore, up 27 per cent against the comparable nine-month period a year ago. Milind Thatte, Managing Director, P&G Health ..

7 injured in attack during protest outside pharma company in Thane, 10 held

Seven persons were injured after allegedly being attacked by a group of workers staging a protest outside a pharmaceutical company in Thane district of Maharashtra, police said on Wednesday. The police have registered a case against 10 attackers in connection with the incident which took place on Monday near the company's premises in the Maharashtra Industrial Development Corporation (MIDC) area in Ambernath, they said. According to the FIR, the incident occurred at around 12.30 pm on Monday when the accused, who were staging a sit-in protest outside the company's premises, spotted a group of people entering the factory. The reason for the protest was not specified. The accused, suspecting that the people entering the company were hired to replace them, allegedly hit the victims and also attacked them with sticks. They chased away the victims and threatened them with dire consequences if they reported to work at the company, an official from Shivaji Nagar police station said. Sev

Drugmakers Glenmark Pharma, Cipla plan to step up US manufacturing

The US already contributes a significant share, around a quarter, of Cipla's total revenues

US judge denies injunction, restricts copies of weight-loss drug Ozempic

A US judge earlier barred compounders from making copies of Eli Lilly's Zepbound and Mounjaro

Is your heartburn pill safe? Panel recommends banning ranitidine in India

An expert panel has recommended suspending ranitidine after tests found cancer-linked NDMA levels in half the samples, bringing India closer to a nationwide ban

DRL trims workforce costs by 25% amid Revlimid-linked margin strain

There are 21,757 permanent employees on company rolls as on March 31, 2024; cost optimisation to offset margin pressure due to declining Revlimid sales

Morepen to hire 1,000 medical representatives to boost formulations biz

Morepen Laboratories on Friday said it will add more than 1,000 medical representatives over the next three years, with over 200 team members expected to join in FY26 alone. The company aims to strengthen its formulations business in the market through new hirings. "This expansion represents a pivotal moment in Morepen's journey as we sharpen our focus on the expanding domestic finished dosage market," Morepen Laboratories Chairman and MD Sushil Suri said in a statement. With significant increase in the sales force and enhanced reach to doctors, pharmacies, and patients, the drugmaker is setting the stage for getting a bigger pie in the Indian pharmaceutical market valued at Rs 2.38 lakh crore, yielding higher gross margins and better returns for stakeholders in the long run, he added. Currently, Morepen's formulation business stands around Rs 325 crore, and the company is targeting to touch Rs 1,000 crore in the next five years. This goal will be supported by an aggressive expans

Which Indian companies may be hit hard if US announces tariffs on pharma?

India is one of the top suppliers of generic (low-cost) medicines to the US

Lupin announces acquisition of UK-Based Renascience Pharma for GBP 12.3 mn

Renascience, incorporated in 2015, supplies niche branded bio-generic products catering to primary and secondary care in the UK

Drug prices may rise in US if Indian pharma firms pass on Trump's tariff

The US administration has not made announcements yet on sector-specific tariffs

Agilus Diagnostics lowers marketing spend 2 years after rebranding

In FY25, an additional Rs 50 crore was spent on marketing over and above the usual budget